PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY

被引:417
作者
KANTARJIAN, HM
SMITH, TL
OBRIEN, S
BERAN, M
PIERCE, S
TALPAZ, M
ROBERTSON, L
KOLLER, C
ESTEY, E
KEATING, MJ
机构
[1] M.D. Anderson Cancer Center, Houston, TX
[2] Department of Hematology, Box 61, M.D. Anderson Cancer Center, Houston, TX 77030
关键词
LEUKEMIA; MYELOID; CHRONIC; INTERFERON-ALPHA; CYTOGENETICS; BASOPHILS; SPLENOMEGALY;
D O I
10.7326/0003-4819-122-4-199502150-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine whether a cytogenetic response after interferon-alpha therapy in patients with chronic myelogenous leukemia is independently associated with improved survival. Design: Retrospective analysis. Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-alpha-based programs between 1982 and 1990. Intervention: Therapy with daily subcutaneous interferon-alpha given at 5 x 10(6) U/m(2) body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule. Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P less than or equal to 0.01) and of survival outcomes (P less than or equal to 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001). Conclusion: Achieving a cytogenetic response with interferon-alpha therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.
引用
收藏
页码:254 / 261
页数:8
相关论文
共 21 条
[1]  
ALIMENA G, 1988, BLOOD, V72, P642
[2]   ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].
ANDERSON, JR ;
CAIN, KC ;
GELBER, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].
DALEY, GQ ;
VANETTEN, RA ;
BALTIMORE, D .
SCIENCE, 1990, 247 (4944) :824-830
[5]  
GOLDMAN JM, 1993, BLOOD, V82, P2235
[6]  
GOLDMAN JM, 1990, LEUKEMIA, V4, P163
[7]   RANDOMIZED COMPARISON OF BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA - PROLONGATION OF SURVIVAL BY HYDROXYUREA [J].
HEHLMANN, R ;
HEIMPEL, H ;
HASFORD, J ;
KOLB, HJ ;
PRALLE, H ;
HOSSFELD, DK ;
QUEISSER, W ;
LOFFLER, H ;
HEINZE, B ;
GEORGII, A ;
VONWUSSOW, P ;
BARTRAM, C ;
GRIESSHAMMER, M ;
BERGMANN, L ;
ESSERS, U ;
FALGE, C ;
HOCHHAUS, A ;
QUEISSER, U ;
SICK, C ;
MEYER, P ;
SCHMITZ, N ;
VERPOORT, K ;
EIMERMACHER, H ;
WALTHER, F ;
WESTERHAUSEN, M ;
KLEEBERG, UR ;
HEILEIN, A ;
KABISCH, A ;
BARZ, C ;
ZIMMERMANN, R ;
MEURET, G ;
TICHELLI, A ;
BERDEL, WE ;
KANZ, L ;
ANGER, B ;
TIGGES, FJ ;
SCHMID, L ;
BROCKHAUS, W ;
ZANKOVICH, R ;
SCHLAFER, U ;
WEISSENFELS, I ;
MAINZER, K ;
TOBLER, A ;
PERKER, M ;
HOHNLOSER, J ;
MESSENER, D ;
THIELE, J ;
BUHR, T ;
ANSARI, H .
BLOOD, 1993, 82 (02) :398-407
[8]  
KANTARJIAN HM, 1993, BLOOD, V82, P691
[9]   PROPOSAL FOR A SIMPLE SYNTHESIS PROGNOSTIC STAGING SYSTEM IN CHRONIC MYELOGENOUS LEUKEMIA [J].
KANTARJIAN, HM ;
KEATING, MJ ;
SMITH, TL ;
TALPAZ, M ;
MCCREDIE, KB .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (01) :1-8
[10]  
KANTARJIAN HM, 1985, BLOOD, V66, P1326